Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche reports positive subcutaneous MabThera trial data

Roche reports positive subcutaneous MabThera trial data

11th December 2012

Roche has announced positive data from a pair of clinical studies assessing the benefits of subcutaneously-administered MabThera.

Pivotal data from the trials showed that this method of delivery allows the cancer drug to be administered over approximately five minutes, without compromising the proven efficacy and safety of the therapy.

The five-minute treatment time observed with this approach compares very favourably to the 2.5 hours taken using intravenous infusion, thus reducing pharmacy time and helping to conserve hospital resources.

MabThera was originally released in 1997 and is approved for use in the treatment of several blood cancers, including non-Hodgkin lymphoma and chronic lymphocytic leukaemia.

Hal Barron, chief medical officer and head for global product development at Roche, said: "As a leader in innovative treatments for cancer, Roche is committed to a broad research program of investigational medicines and innovative ways to administer them."

This comes after the firm also recently reported positive data from a phase III trial of the breast cancer drug Perjeta earlier this month.ADNFCR-8000103-ID-801504277-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.